On March 11, 2019. Molecular Partners AG (SIX: MOLN), a clinical-stage biotech company pioneering the use of DARPin therapeutics* to treat serious diseases, reported that it will present at the Cowen and Company 39th Annual Health Care Conference on Tuesday, March 12, 2019 at 12:00 – 12:30 PM Eastern Time (5:00 PM CET) (Press release, Molecular Partners, MAR 11, 2019, View Source [SID1234534193]). The presentation, followed by a Q&A session, will be hosted by Dr. Patrick Amstutz, CEO of Molecular Partners.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Next to highlighting the progress of the clinical DARPin compounds, the presentation will outline the evolution of the company’s therapeutic design space in oncology research, including the recent strategic partnership with Amgen on MP0310 (FAP x 4-1BB). The presentation will also outline the initiation of a research project to explore DARPin molecules targeting peptide MHC complexes supported by Gilead. The ability to target peptide MHC complexes with DARPin molecules has the potential to open the target space significantly, as these targets have been notoriously difficult to be addressed by any antibody-based approaches.